Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
As such, qCLUE marries decades of development with the quadratic speedup provided by quantum computers. We numerically test qCLUE in several scenarios, demonstrating its effectiveness and proving it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback